Patents by Inventor Mohan Srinivasan

Mohan Srinivasan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11802162
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: October 31, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Changyu Wang, Nils Lonberg, Alan J. Korman, Mark J. Selby, Mohan Srinivasan, Karla A. Henning, Michelle Minhua Han, Guodong Chen, Richard Huang, Indrani Chakraborty, Haichun Huang, Susan Wong, Huiming Li
  • Publication number: 20230295346
    Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.
    Type: Application
    Filed: March 9, 2023
    Publication date: September 21, 2023
    Inventors: Stanley R. Krystek, JR., Yong Zhang, Gregory D. Vite, Arvind Rajpal, Chetana Rao-Naik, Paul E. Morin, Mohan Srinivasan, Zheng Lin, Virginie Lafont, Alla Pritsker
  • Publication number: 20230272100
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
    Type: Application
    Filed: August 11, 2022
    Publication date: August 31, 2023
    Applicant: Bristol-Myers Squibb Company
    Inventors: Zhehong CAI, Indrani CHAKRABORTY, Marie-Michelle Navarro GARCIA, Thomas D. KEMPE, Alan J. KORMAN, Alexander T. KOZHICH, Hadia LEMAR, Mark MAURER, Christina Maria MILBURN, Michael QUIGLEY, Xiang SHAO, Mohan SRINIVASAN, Kent THUDIUM, Susan Chien-Szu WONG, Jochem GOKEMEIJER, Xi-Tao WANG, Han CHANG, Patrick GUIRNALDA
  • Publication number: 20230272079
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
    Type: Application
    Filed: February 9, 2023
    Publication date: August 31, 2023
    Applicants: E.R. SQUIBB & SONS, L.L.C., Ono Pharmaceutical Co., LTD.
    Inventors: Alan J. KORMAN, Mohan SRINIVASAN, Changyu WANG, Mark J. SELBY, Bingliang CHEN, Josephine M. CARDARELLI, Haichun HUANG
  • Patent number: 11708405
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: July 25, 2023
    Assignee: BRISTOL-MYERS QUIBB COMPANY
    Inventors: Mohan Srinivasan, Shrikant Deshpande, Qihong Zhao, Huadong Sun, Ginger Rakestraw, Guodong Chen, Richard Y. Huang, Steven Sheriff, Cristian Rodriguez, John P. Throup, Rose A. Dibella
  • Publication number: 20230220102
    Abstract: Provided herein are antibodies that specifically bind to CD25. Also provided herein are methods of making the antibodies described, and methods of use thereof. For example, the CD25 antibodies may be used therapeutically to treat cancer or autoimmune diseases.
    Type: Application
    Filed: May 13, 2021
    Publication date: July 13, 2023
    Inventors: Phung Tu GIP, Bing LI, Matthew P. GREVING, Matt LUNDBERG, Mohan SRINIVASAN
  • Patent number: 11623965
    Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: April 11, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stanley R. Krystek, Jr., Yong Zhang, Gregory D. Vite, Arvind Rajpal, Chetana Rao-Naik, Paul E. Morin, Mohan Srinivasan, Zheng Lin, Virginie Lafont, Alla Pritsker
  • Publication number: 20230077348
    Abstract: The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention arc also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.
    Type: Application
    Filed: May 2, 2022
    Publication date: March 16, 2023
    Applicant: Bristol-Myers Squibb Company
    Inventors: Nils LONBERG, Mohan SRINIVASAN
  • Publication number: 20230061544
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.
    Type: Application
    Filed: June 16, 2022
    Publication date: March 2, 2023
    Applicant: E.R. Squibb & Sons, L. L. C.
    Inventors: Alan J. KORMAN, Mark J. SELBY, Changyu WANG, Mohan SRINIVASAN, David B. PASSMORE, Haichun HUANG, Haibin CHEN
  • Publication number: 20230050665
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
    Type: Application
    Filed: June 30, 2021
    Publication date: February 16, 2023
    Inventors: Changyu WANG, Nils LONBERG, Alan J. KORMAN, Mark J. SELBY, Mohan SRINIVASAN, Karla HENNING, Michelle Minhua HAN, Guodong CHEN, Richard HUANG, Indrani CHAKRABORTY, Haichun HUANG, Susan WONG, Huiming LI
  • Publication number: 20230051701
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
    Type: Application
    Filed: May 5, 2022
    Publication date: February 16, 2023
    Inventors: Nils Lonberg, Alan J. Korman, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Ming Lei, Emanuela Sega, Angela Goodenough, Maria N. Jure-Kunkel, Guodong Chen, John S. Sack, Richard Huang, Martin J. Corbett, Joseph E. Myers, JR., Liang Schweizer, Sandra V. Hatcher, Haichun Huang, Pingping Zhang
  • Publication number: 20230016112
    Abstract: Provided herein engineered polypeptides that comprise a combination of spatially-associated topological constraints, wherein at least one constraint is derived from a CD25 reference target, and methods of selecting said engineered polypeptides. Further provided are methods of using the engineered polypeptides, including as positive and/or negative selection molecules in methods of screening a library of binding molecules such as antibodies. Further provided herein are CD25 antibodies selected using these engineered polypeptides.
    Type: Application
    Filed: May 13, 2021
    Publication date: January 19, 2023
    Inventors: Matthew P. GREVING, Phung Tu GIP, Mohan SRINIVASAN, Andrew MORIN, Kevin Eduard HAUSER, Jordan R. WILLIS, Cody A. MOORE, Christian BARRETT, Alex T. TAGUCHI, Angeles ESTELLES
  • Patent number: 11466092
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: October 11, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zhehong Cai, Indrani Chakraborty, Marie-Michelle Navarro Garcia, Thomas D. Kempe, Alan J. Korman, Alexander T. Kozhich, Hadia Lemar, Mark Maurer, Christina Maria Milburn, Michael Quigley, Xiang Shao, Mohan Srinivasan, Kent Thudium, Susan Chien-Szu Wong, Jochem Gokemeijer, Xi-Tao Wang, Han Chang, Patrick Guirnalda
  • Publication number: 20220281980
    Abstract: The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.
    Type: Application
    Filed: January 24, 2022
    Publication date: September 8, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventors: Michelle Renee KUHNE, Alan J. KORMAN, Haichun HUANG, Yiming YIN, Robert F. GRAZIANO, Natalie A. BEZMAN, Pavel STROP, Richard Y. HUANG, Guodong CHEN, Mohan SRINIVASAN, Peter Sung Keun LEE, Gamze Ozlem CAMDERE
  • Patent number: 11408889
    Abstract: Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: August 9, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Xi-Tao Wang, Olufemi A. Adelakun, Anne C. Lewin, Alan J. Korman, Mark J. Selby, Changyu Wang, Haichun Huang, Karla A. Henning, Nils Lonberg, Mohan Srinivasan, Michelle Minhua Han, Guodong Chen, Richard Y. Huang, Indrani Chakraborty, Susan Chien-Szu Wong, Huiming Li
  • Publication number: 20220175921
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
    Type: Application
    Filed: November 19, 2021
    Publication date: June 9, 2022
    Inventors: Changyu WANG, Nils LONBERG, Alan J. KORMAN, Mark J. SELBY, Mohan SRINIVASAN, Karla A. HENNING, Michelle Minhua HAN, Guodong CHEN, Richard Y. HUANG, Indrani CHAKRABORTY, Haichun HUANG, Susan Chien-Szu WONG, Huiming LI, Bryan C. BARNHART, Aaron P. YAMNIUK, Ming LEI, Liang SCHWEIZER, Sandra V. HATCHER, Arvind RAJPAL
  • Patent number: 11352440
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: June 7, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Nils Lonberg, Alan J. Korman, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Ming Lei, Emanuela Sega, Angela Goodenough, Maria N. Jure-Kunkel, Guodong Chen, John S. Sack, Richard Y. Huang, Martin J. Corbett, Joseph E. Myers, Jr., Liang Schweizer, Sandra V. Hatcher, Haichun Huang, Pingping Zhang
  • Patent number: 11345752
    Abstract: The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: May 31, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Nils Lonberg, Mohan Srinivasan
  • Patent number: 11242393
    Abstract: The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: February 8, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michelle Renee Kuhne, Alan J. Korman, Haichun Huang, Yiming Yin, Robert F. Graziano, Natalie A. Bezman, Pavel Strop, Richard Y. Huang, Guodong Chen, Mohan Srinivasan, Peter Sung Keun Lee, Gamze Ozlem Camdere
  • Publication number: 20220010301
    Abstract: Provided herein are functional interface mimics (FIMs), which mimic a functional interface of an interface protein. The FIMs comprise at least one peptide and at least one linking moiety, such as a linker or a cross-link. In some embodiments, the FIMs comprise at least two peptides connected by at least one linker. In some embodiments, the FIM is an immunogen. Also provided herein are methods of selected an FIM, and methods of producing an antibody using an FIM.
    Type: Application
    Filed: November 13, 2019
    Publication date: January 13, 2022
    Inventors: Mohan SRINIVASAN, Matthew GREVING